Radiopharm Theranostics Limited(RADX)Earnings, Financials & Key Ratios
RADX•NASDAQ
Price updated Jun 19, 2026
AboutRadiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.Show more
- Revenue$4M+1114.3%
- EBITDA-$38M-13.9%
- Net Income-$38M+20.0%
- EPS (Diluted)-5.28+85.3%
- Gross Margin1.08%-98.9%
- EBITDA Margin-1050.43%+90.6%
- Operating Margin-1050.63%+91.4%
- Net Margin-1055.27%+93.4%
- ROE-109.2%+17.0%
RADX Key Insights
Radiopharm Theranostics Limited (RADX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RADX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RADX Price & Volume
Radiopharm Theranostics Limited (RADX) stock price & volume — 10-year historical chart
Loading chart...
RADX Growth Metrics
Radiopharm Theranostics Limited (RADX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years643.76%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-50.08%
5 Years-50.08%
3 Years-57.97%
Last Year-60.59%
RADX Peer Comparison
Radiopharm Theranostics Limited (RADX) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RNW | 2.3B | 6.32 | 20.01 | 43.31% | 7.82% | 7.42% | 5.40 | |
 RNAZ | 4.47M | 4.70 | -0.09 | -99.39% | ||||
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 PRTC | 41.78M | 17.31 | -0.38 | -3.5% | -6.25% | -16.12% | 0.06 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 IART | 1.37B | 17.58 | -2.61 | 1.53% | -30.15% | -47.65% | 1.95 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 |
Compare RADX vs Peers
Radiopharm Theranostics Limited (RADX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RADX Income Statement
Radiopharm Theranostics Limited (RADX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|
Sales/Revenue | 8.83K | 292.36K | 299.23K | 3.63M |
Revenue Growth % | - | 3210.6% | 2.35% | 1114.27% |
Cost of Goods Sold | 0 | 0 | 0 | 3.59M |
COGS % of Revenue | - | - | - | 98.92% |
Gross Profit | 8.83K▲ 0% | 292.36K▲ 3210.6% | 299.23K▲ 2.3% | 39.28K▼ 86.9% |
Gross Margin % | 100% | 100% | 100% | 1.08% |
Gross Profit Growth % | - | 3210.6% | 2.35% | -86.87% |
Operating Expenses | 19.93M | 34.8M | 36.92M | 38.21M |
OpEx % of Revenue | 225627.71% | 11903.33% | 12338.44% | 1051.71% |
Selling, General & Admin | 10.85M | 13.02M | 15.22M | 16.53M |
SG&A % of Revenue | 122839.04% | 4453.78% | 5085.81% | 454.83% |
Research & Development | 4.12M | 13.8M | 17.56M | 27.52M |
R&D % of Revenue | 46707.64% | 4720.37% | 5868.23% | 757.28% |
Other Operating Expenses | 4.95M | 7.98M | 4.14M | -5.83M |
Operating Income | -19.92M▲ 0% | -34.51M▼ 73.3% | -36.62M▼ 6.1% | -38.17M▼ 4.2% |
Operating Margin % | -225527.71% | -11803.33% | -12238.44% | -1050.63% |
Operating Income Growth % | - | -73.27% | -6.12% | -4.24% |
EBITDA | -16.93M | -31.21M | -33.49M | -38.17M |
EBITDA Margin % | -191766.14% | -10675.76% | -11193.66% | -1050.43% |
EBITDA Growth % | - | -84.3% | -7.31% | -13.95% |
D&A (Non-Cash Add-back) | 2.98M | 3.3M | 3.13M | 7.33K |
EBIT | -20.94M | -34.49M | -47.21M | -38.17M |
Net Interest Income | -9.35M | 58.94K | -592.4K | 333.11K |
Interest Income | 0 | 145.03K | 50.48K | 888.2K |
Interest Expense | 9.35M | 86.09K | 642.89K | 65.3K |
Other Income/Expense | -10.38M | -65.1K | -11.23M | -65.3K |
Pretax Income | -30.29M▲ 0% | -34.57M▼ 14.1% | -47.85M▼ 38.4% | -38.24M▲ 20.1% |
Pretax Margin % | -343048.15% | -11825.59% | -15992.07% | -1052.43% |
Income Tax | 44.4K | 38.01K | 96.36K | 103.29K |
Effective Tax Rate % | -0.15% | -0.11% | -0.2% | -0.27% |
Net Income | -30.34M▲ 0% | -34.61M▼ 14.1% | -47.95M▼ 38.5% | -38.34M▲ 20.0% |
Net Margin % | -343550.89% | -11838.59% | -16024.28% | -1055.27% |
Net Income Growth % | - | -14.08% | -38.54% | 20.04% |
Net Income (Continuing) | -30.34M | -34.61M | -47.95M | -38.34M |
Discontinued Operations | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 1.19M | -769.28K | -1.92M |
EPS (Diluted) | -29.76▲ 0% | -33.00▼ 10.9% | -36.00▼ 9.1% | -5.28▲ 85.3% |
EPS Growth % | - | -10.89% | -9.09% | 85.33% |
EPS (Basic) | -29.76 | -33.00 | -36.00 | -5.28 |
Diluted Shares Outstanding | 1.02M | 1.02M | 1.29M | 6.94M |
Basic Shares Outstanding | 1.02M | 1.02M | 1.29M | 6.94M |
Dividend Payout Ratio | - | - | - | - |
RADX Balance Sheet
Radiopharm Theranostics Limited (RADX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|
Total Current Assets | 27.26M | 16.3M | 22.85M | 39.85M |
Cash & Short-Term Investments | 26.98M | 11.7M | 18.58M | 29.12M |
Cash Only | 26.98M | 11.7M | 18.58M | 29.12M |
Short-Term Investments | 0 | 0 | 0 | 0 |
Accounts Receivable | 56.48K | 4.47M | 987.41K | 10.4M |
Days Sales Outstanding | 2.33K | 5.58K | 1.2K | 1.04K |
Inventory | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - |
Other Current Assets | 228.82K | 133.13K | 3.29M | 337.09K |
Total Non-Current Assets | 56.12M | 58.65M | 49.19M | 46.63M |
Property, Plant & Equipment | 1.58K | 68.33K | 60.8K | 53.47K |
Fixed Asset Turnover | 5.60x | 4.28x | 4.92x | 67.96x |
Goodwill | 0 | 0 | 0 | 0 |
Intangible Assets | 56.08M | 58.54M | 49.09M | 46.57M |
Long-Term Investments | 0 | 0 | 40K | 0 |
Other Non-Current Assets | 40K | 40K | 0 | 0 |
Total Assets | 83.38M▲ 0% | 74.95M▼ 10.1% | 72.04M▼ 3.9% | 86.48M▲ 20.1% |
Asset Turnover | 0.00x | 0.00x | 0.00x | 0.04x |
Asset Growth % | - | -10.11% | -3.89% | 20.05% |
Total Current Liabilities | 7.88M | 13.23M | 17.58M | 14.93M |
Accounts Payable | 1.19M | 2.96M | 6.43M | 6.35M |
Days Payables Outstanding | - | - | - | 644.6 |
Short-Term Debt | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 1.72M |
Other Current Liabilities | 5.73M | 8.11M | 6.72M | 3.87M |
Current Ratio | 3.46x | 1.23x | 1.30x | 2.67x |
Quick Ratio | 3.46x | 1.23x | 1.30x | 2.67x |
Cash Conversion Cycle | - | - | - | - |
Total Non-Current Liabilities | 12.54M | 16.14M | 27.11M | 28.68M |
Long-Term Debt | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12.54M | 16.14M | 27.11M | 28.68M |
Total Liabilities | 20.42M | 29.37M | 44.68M | 43.61M |
Total Debt | 0 | 0 | 0 | 0 |
Net Debt | -26.98M | -11.7M | -18.58M | -29.12M |
Debt / Equity | - | - | - | - |
Debt / EBITDA | - | - | - | - |
Net Debt / EBITDA | - | - | - | - |
Interest Coverage | -2.13x | -400.83x | -56.96x | -584.59x |
Total Equity | 62.96M▲ 0% | 45.58M▼ 27.6% | 27.35M▼ 40.0% | 42.87M▲ 56.7% |
Equity Growth % | - | -27.61% | -39.99% | 56.73% |
Book Value per Share | 61.76 | 44.71 | 21.23 | 6.18 |
Total Shareholders' Equity | 62.96M | 44.38M | 28.12M | 44.79M |
Common Stock | 86.76M | 97.23M | 100.68M | 176.56M |
Retained Earnings | -30.82M | -65.35M | -111.34M | -145.73M |
Treasury Stock | 0 | 0 | 0 | 0 |
Accumulated OCI | 7.03M | 10.36M | 37.93M | 13.12M |
Minority Interest | 0 | 1.19M | -769.28K | -1.92M |
RADX Cash Flow Statement
Radiopharm Theranostics Limited (RADX) cash flow — operating, investing & free cash flow history
| Metric | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|
Cash from Operations | -9.92M | -23.2M | -22.98M | -36.65M |
Operating CF Margin % | -112282.35% | -7936.06% | -7678.4% | -1008.57% |
Operating CF Growth % | - | -133.99% | 0.97% | -59.49% |
Net Income | -30.34M | -34.61M | -47.95M | 0 |
Depreciation & Amortization | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 20.42M | 11.41M | 24.97M | -36.65M |
Working Capital Changes | 0 | 0 | 0 | 0 |
Change in Receivables | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 |
Cash from Investing | -28.37M | -1.53M | -320K | 1.77M |
Capital Expenditures | -2.75K | -45.31K | 0 | 0 |
CapEx % of Revenue | 31.13% | 15.5% | - | - |
Acquisitions | 0 | 0 | 0 | 0 |
Investments | - | - | - | - |
Other Investing | -28.37M | -1.49M | -320K | 1.77M |
Cash from Financing | 65.11M | 9.22M | 30.2M | 45.43M |
Debt Issued (Net) | -59K | 0 | 2.2M | -1.9M |
Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K |
Dividends Paid | 0 | 0 | 0 | 0 |
Share Repurchases | -4.83M | -854.76K | -1.53M | 0 |
Other Financing | 0 | 0 | -117K | -6.65M |
Net Change in Cash | 26.95M▲ 0% | -15.28M▼ 156.7% | 6.88M▲ 145.0% | 10.54M▲ 53.3% |
Free Cash Flow | -38.25M▲ 0% | -24.73M▲ 35.3% | -22.98M▲ 7.1% | -36.65M▼ 59.5% |
FCF Margin % | -433182.02% | -8459.63% | -7678.4% | -1008.57% |
FCF Growth % | - | 35.35% | 7.1% | -59.49% |
FCF per Share | -37.52 | -24.26 | -17.84 | -5.28 |
FCF Conversion (FCF/Net Income) | 0.33x | 0.67x | 0.48x | 0.96x |
Interest Paid | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 |
RADX Key Ratios
Radiopharm Theranostics Limited (RADX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Return on Equity (ROE) | -48.19% | -63.77% | -131.49% | -109.2% |
Return on Invested Capital (ROIC) | -41.51% | -74.09% | -128.77% | -254.12% |
Gross Margin | 100% | 100% | 100% | 1.08% |
Net Margin | -343550.89% | -11838.59% | -16024.28% | -1055.27% |
Interest Coverage | -2.13x | -400.83x | -56.96x | -584.59x |
FCF Conversion | 0.33x | 0.67x | 0.48x | 0.96x |
Revenue Growth | - | 3210.6% | 2.35% | 1114.27% |
Related:RADX Dividend History·RADX Revenue History·RADX Price History·RADX P/E History·RADX Financial Ratios·RADX Institutional Holders
RADX Frequently Asked Questions
Radiopharm Theranostics Limited (RADX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Radiopharm Theranostics Limited (RADX) reported $3.6M in revenue for fiscal year 2024. This represents a 41044% increase from $0.0M in 2021.
Radiopharm Theranostics Limited (RADX) grew revenue by 1114.3% over the past year. This is strong growth.
Radiopharm Theranostics Limited (RADX) reported a net loss of $38.3M for fiscal year 2024.
Dividend & Returns
Radiopharm Theranostics Limited (RADX) has a return on equity (ROE) of -109.2%. Negative ROE indicates the company is unprofitable.
Radiopharm Theranostics Limited (RADX) had negative free cash flow of $36.6M in fiscal year 2024, likely due to heavy capital investments.